|
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. |
Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. Journal of Clinical Apheresis 2013; 28(5): 359-367 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Anti-Bacterial Agents /administration & Antigens, CD34 /metabolism; Antineoplastic Agents /administration & Boronic Acids /administration & Bortezomib; Cohort Studies; Cyclophosphamide /administration & Female; Granulocyte Colony-Stimulating Factor /administration & Health Care Costs; Hematopoietic Stem Cell Mobilization /economics /methods; Heterocyclic Compounds /administration & Humans; Leukocytes, Mononuclear /cytology; Male; Middle Aged; Multiple Myeloma /therapy; Peripheral Blood Stem Cell Transplantation /methods; Pyrazines /administration & Thalidomide /administration & Time Factors; Transplantation Conditioning /methods; Treatment Outcome; derivatives /economics; dosage /analogs & dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22013048920 Date bibliographic record published 19/12/2013 |
|
|
|